APA

Savage L., Goodfield M., Horton L., Watad A., Hensor E., Emery P., Wakefield R., Wittmann M. & McGonagle D. (20191227). Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. : Arthritis & rheumatology (Hoboken, N.J.).

Chicago

Savage Laura, Goodfield Mark, Horton Laura, Watad Abdulla, Hensor Elizabeth, Emery Paul, Wakefield Richard, Wittmann Miriam and McGonagle Dennis. 20191227. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. : Arthritis & rheumatology (Hoboken, N.J.).

Harvard

Savage L., Goodfield M., Horton L., Watad A., Hensor E., Emery P., Wakefield R., Wittmann M. and McGonagle D. (20191227). Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. : Arthritis & rheumatology (Hoboken, N.J.).

MLA

Savage Laura, Goodfield Mark, Horton Laura, Watad Abdulla, Hensor Elizabeth, Emery Paul, Wakefield Richard, Wittmann Miriam and McGonagle Dennis. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. : Arthritis & rheumatology (Hoboken, N.J.). 20191227.